MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Ono Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 08 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.